PDCD1 and non-small cell lung carcinoma: Considering the increasing number of patients on anti‐PD‐1 therapy, high expenditure of treatment, and large subset of NSCLC patients in China, the identification of predictive biomarkers that may be used to select suitable patient populations likely to significantly benefit from ICI therapy remains a major challenge.